<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180413</url>
  </required_header>
  <id_info>
    <org_study_id>26169</org_study_id>
    <nct_id>NCT01180413</nct_id>
  </id_info>
  <brief_title>Intensive Vasodilator Therapy in Patients With Essential Hypertension</brief_title>
  <acronym>Vasomore</acronym>
  <official_title>Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether add-on of intensive vasodilator therapy can&#xD;
      improve the coronary perfusion and reduce the total peripheral resistance in patients with&#xD;
      ongoing treatment for essential hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morphological changes are observed in the microvasculature of patients with essential&#xD;
      hypertension. The lumen diameter is reduced in resistance arteries, but with no change in&#xD;
      vessel cross-sectional area or wall mass. These structural changes are termed inward&#xD;
      eutrophic remodelling and results in an increased wall:lumen ratio, caused by rearrangement&#xD;
      of cell matrix and not by hypertrophy of smooth muscle cells in the vascular wall as observed&#xD;
      in secondary forms of hypertension. The morphological changes also occur in the coronary&#xD;
      arteries and cause a reduction in the ability to increase coronary perfusion as response to&#xD;
      increased cardiac work. This is observed as a reduced coronary flow reserve in patients with&#xD;
      sustained hypertension.&#xD;
&#xD;
      Two recently published clinical studies associates an increase in media:lumen ratio with an&#xD;
      increased risk of cardiovascular events, and it therefore seems beneficial to normalize the&#xD;
      vascular structure in patients with essential hypertension. It has previously been&#xD;
      demonstrated that reversion of vascular remodelling and thereby normalization of the vascular&#xD;
      structure, requires vasodilatation and not just blood pressure reduction, suggesting that&#xD;
      patients with essential hypertension can benefit from antihypertensive treatment aimed to&#xD;
      induce vasodilatation.&#xD;
&#xD;
      The purpose of this study is to determine whether add-on of intensive vasodilator therapy can&#xD;
      improve the coronary perfusion (coronary flow reserve) and reduce the total peripheral&#xD;
      resistance in patients with ongoing treatment for essential hypertension. We also aim to&#xD;
      investigate whether changes in coronary flow reserve correlates better to changes in total&#xD;
      peripheral resistance than changes in blood pressure. Particularly we aim to study if&#xD;
      patients with high total peripheral resistance, despite blood pressure control, can benefit&#xD;
      from intensive vasodilating therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Puls Wave Velocity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass</measure>
    <time_frame>6 months</time_frame>
    <description>Determined with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Ambulatory Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Vascular Resistance</measure>
    <time_frame>6 months</time_frame>
    <description>By Innocor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal forearm vascular resistance</measure>
    <time_frame>6 months</time_frame>
    <description>By pletysmography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Vasodilatory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive intensive vasodilatory treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment</description>
    <arm_group_label>Vasodilatory</arm_group_label>
    <other_name>Amlodipin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.</description>
    <arm_group_label>Vasodilatory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine</intervention_name>
    <description>Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment</description>
    <arm_group_label>Vasodilatory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment</description>
    <arm_group_label>Vasodilatory</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ongoing antihypertensive treatment for &gt;3 months&#xD;
&#xD;
          -  Blood pressure &gt;120/75 during antihypertensive treatment&#xD;
&#xD;
          -  Ejection fraction &gt; 45%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood pressure &gt;160/100&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  fertile women not using safe contraceptives&#xD;
&#xD;
          -  known secondary hypertension&#xD;
&#xD;
          -  valvular disease of haemodynamic significance&#xD;
&#xD;
          -  known endocrine disease, nephropathy or hepatic disease&#xD;
&#xD;
          -  present malignant disease&#xD;
&#xD;
          -  known psychiatric disease&#xD;
&#xD;
          -  abnormal lab tests of clinical significance&#xD;
&#xD;
          -  known allergy to any study medication&#xD;
&#xD;
          -  body mass index &gt; 35&#xD;
&#xD;
          -  Ongoing antihypertensive treatment with a combination of ACE-inhibitor and Calcium&#xD;
             antagonist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Engholm Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University and Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Norling Mathiasen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University and Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Henrik Buus, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University and Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashkan Eftekhari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University and Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital - dept. cardiology (A)</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Engholm Pedersen</investigator_full_name>
    <investigator_title>MD/PhD-Student</investigator_title>
  </responsible_party>
  <keyword>Inward eutrophic remodelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Lercanidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

